Five Prime Lands Blow On Gastric Cancers With FGFR2b Antibody
Positive Top-Line Data From Phase II FIGHT Trial
A potential first-in-class FGFR2b-targeted monoclonal antibody, bemarituzumab, has shown top-line benefits in the Phase II FIGHT study in advanced gastric or gastroesophageal junction cancers.
You may also be interested in...
Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.
In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.
Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.